Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity

OBJECTIVE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors exhibit cardioprotective properties in patients with diabetes. However, SGLT2 is not expressed in the heart, and the underlying molecular mechanisms are not fully understood. We investigated whether the SGLT2 inhibitor luseogliflozin exert...

Full description

Bibliographic Details
Main Authors: Fukui, T. (Author), Hiromura, M. (Author), Kawakami, R. (Author), Mori, Y. (Author), Ohara, M. (Author), Osaka, N. (Author), Saito, T. (Author), Shiraga, Y. (Author), Terasaki, M. (Author), Yamagishi, S.-I (Author), Yashima, H. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
Cariporide
diabetic cardiomyopathy
fibrosis
luseogliflozin
sodium-glucose cotransporter-2 inhibitor
sodium-hydrogen exchanger-1
transforming growth factor-β2
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items